Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agents by Zhu, Y et al.
ELSEVIER 
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,....-,HE SYNERGISTIC combination of immunosuppres-
.1 sive drugs is thought to provide a better therapeutic 
index with fewer side effects than single-drug therapy. 
Tacrolimus (FK 506), an inhibitor of interleukin-2 (IL-2) 
synthesis, is a potent immunosuppressive agent that has 
various adverse effects including nephrotoxicity, neurotox-
icity, diabetogenesis. and infectious complications.! Exper-
imental models have shown that antimetabolic agents are 
good candidates for combination with tacrolimus.2•3 Several 
antimetabolic agents. azathioprine (AZA). mizoribine 
(MIZ). mycophenolate mofetil (RS), and ethyl o-[N-(p-
carboxyphenyl)-carbamoyIJ-mycophenolate (CAM), were 
tested alone and in combination with tacrolimus to deter-
mine if they could improve canine renal allograft survival. 
while reducing immunosuppression-related adverse events. 
MATERIALS AND METHODS 
Adult mongrel dogs were used for donors and adult beagle dogs 
were used for recipients. Canine kidney transplantation was per-
formed using standard operative procedures. After transplanting 
one kidney allograft into the right iliac fosia. bilateral native 
nephrectomies were performed. Experimental groups were divided 
into single-drug groups and combined-drug groups. The control 
group received no treatment. The FK 506 dose chosen (0.5 mg/kg) 
for this study was one third of the therapeutic dose. Single-drug 
doses of anti metabolites were 0.5 and 1.0 mg/kg of AZA. 2.5 and 
5.0 mg/kg of MIZ. 20 and 40 mg/kg of RS. and 20 and 40 mg/kg of 
CAM. Comhined-dose groups were FK 506 (0.5) + AZA (0.5). FK 
506 (0.5) + MIZ (2.5). FK 506 (0.5) + RS (20). and FK 50" (0.5) 
+ CAM (20). Immunosuppression was given daily for \JO days. 
Animals surviving \JO days were killed. Creatinine (Cr). blood urea 
nitrogen (BUN). aspartate aminotransferase (AST). alanine ami-
notransferase (ALT). alkaline phosphatase (AP). and hlood glu-
cose (GLu) were monitored at least twice weekly. 
RESULTS 
Single treatment with all agents. except AZA. was signifi-
cantlv hettcr than control (9.5 days median survival). Tox-
icitv. particularlv gastrointestinal. was seen more frequently 
In the higher-dose ,ingle-treatment groups than in the 
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Fig 1. Renal function and median survival of combination-
treated groups. 
lower-dose single-treatment groups. Because the survival of 
the low and high dose-treated groups was similar. combi-
nation with tacrolimus was only carried out with the lower 
doses of the anti metabolic agents. Survival of animals 
treated with tacrolimus and antimetabolic agents was sig-
nificantly better than that of single antimetabolic agents 
alone for all groups. Survival and renal function of the 
combination groups is shown in Fig I. Only the combination 
of tacrolimus and MIZ was significantly hetter than tacroli-
mus treatment alone (16 days median survival). Toxic 
events in the combination groups were similar to the toxic 
events seen in their respective single-drug groups. but were 
less severe than the toxicity related to the higher single dose 
of the antimetaholic agent. Gastrointestinal toxicity. diar-
rhea. vomiting. and severe weight loss were the most 
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frequent adverse events seen. The RS and CAM groups 
were especially troubled by gastrointestinal toxicity. Only 
two incidences (2.4%) of hepatic toxicity (AST or AL T > 
100 U/L) were seen throughout the study. No bone marrow 
suppression or diabetogenicity was seen. 
DISCUSSION 
This study shows that the combination of tacrolimus and 
antimetabolic agents significantly prolongs canine renal 
allograft survival, without hepatotoxicity, diabetogenicity, 
or bone marrow suppression. The combination of tacroli-
MUS with antimetabolites is synergistic and does not appear 
to increase toxicity. The effect is especially pronounced with 
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the combination of MIZ and tacrolimus. The survival of the 
combined group is not only significantly better than MIZ 
alone. but also tacrolimus alone. MIZ is an especially 
interesting agent for future application to human kidney 
transplantation. Because MIZ is excreted through the kid-
ney, as rejection begins to strike the allograft MIZ levels in 
the blood rise. 
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